Filing Details

Accession Number:
0001209191-21-069350
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-13 20:39:37
Reporting Period:
2021-12-09
Accepted Time:
2021-12-13 20:39:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1636282 Aeglea Biotherapeutics Inc. AGLE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1532219 G. Anthony Quinn 805 Las Cimas Parkway
Suite 100
Austin TX 78746
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-09 43,108 $3.70 318,269 No 4 P Direct
Common Stock Acquisiton 2021-12-10 10,526 $3.75 328,795 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 266,295 Indirect By trusts
Footnotes
  1. The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.55 to $3.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
  2. Includes 963 shares of common stock acquired by the Reporting Person on August 15, 2020, 917 shares of common stock acquired by the Reporting Person on February 17, 2021, and 1,107 shares of common stock acquired by the Reporting Person on August 15, 2021 pursuant to the Issuer's employee stock purchase plan.
  3. The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.62 to $3.80 per share, inclusive.
  4. Includes 57,450 shares of common stock held by the Anthony G. Quinn Irrevocable Trust of 2018 and 208,845 shares of common stock held by the Quinn Family Irrevocable Trust of 2021(together, the "Trusts"). The Reporting Person's spouse is trustee of the Trusts.